Navigation Links
Pharmacopeia to Host First Quarter 2008 Financial Results Webcast and Conference Call
Date:4/23/2008

and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including eight clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Amy P. Sharpless

Corporate Communications

(609) 452-3643

ir_pr@pcop.com

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are av
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
3. Pharmacopeia Announces Management Team Changes
4. Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference
5. Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline
6. Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference
7. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
11. Genmab Announces 2007 First Half Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , September 2, 2015 ... the winners of the 2015 BeHEARD science challenge, a ... offers rare disease researchers, access to the latest life ... its drug repositioning and pathway analytics capability to support ... Nation Foundation in the study of Niemann-Pick Disease Type ...
(Date:9/2/2015)... 2, 2015 Aytu BioScience, Inc. (OTCQB: AYTU), ... urological and related conditions, announced today that it has ... convertible note financing, raising a total of $5.175 million, ... million. Josh Disbrow , Chief ... placement are intended to be used to conduct clinical ...
(Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 /PRNewswire/ ... Sponsoring der Gewinner des Wettbewerbs BeHEARD von 2015 ... einen internationalen vom Rare Genomics Institute. ... Wirksamkeit von Medikamenten für die Behandlung anderer Krankheiten ... wurde, Steven Laffoon und sein Team ...
(Date:9/2/2015)... Diego, CA (PRWEB) , ... September 02, 2015 ... ... troubleshooting faults in manufacturing equipment, to creating professional commercial video content, to analysis ... detailed views of fascinating events that go by too quickly to process with ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... GenVec, Inc. (Nasdaq: GNVC ) today announced that ... Stockholder Rights Plan through the adoption of a new Rights ... on September 7, 2011, which is the date that GenVec,s ... Agreement was adopted in connection with the expiration of the ...
... Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today ... be presenting a corporate overview at the 2011 Wedbush ... 16, 2011, at 8:00 AM ET, in New York. ... on the Investors page of Insmed,s website, http://www.insmed.com ...
... MADISON, Wis., Aug. 11, 2011 Cellular Dynamics International ... Research Grant Program. This grant program will advance researchers, ... cell types derived from them, and the role and ... basic research, drug discovery and development.   ...
Cached Biology Technology:GenVec Renews Stockholder Rights Plan 2GenVec Renews Stockholder Rights Plan 3Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference 2Cellular Dynamics Launches Innovative Research Grant Program 2
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends & ... The Saudi Arabia Biomedical Sensors market is estimated ... 3.64% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/24/2015)... 24, 2015 The consulting company Frost ... biometrics manufacturer DERMALOG and its customized solutions and products for ... Company of the Year Award". DERMALOG is particularly successful with ...   -Cross reference: Picture is available at AP ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... joined The Smart Card Alliance and the EMV Migration ... and the Smart Card Alliance Latin America (SCALA) Chapter ... peers and thought leaders promoting adoption of smart card ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... study from Rhode Island Hospital has found that a change ... contribute to improved outcomes of the victims and to the ... enforcement officers often serve as medical first responders, there is ... or should do, at the scene of an overdose. The ...
... MedNet Solutions , a global life sciences technology ... to announce that Accelovance , an award-winning, full-service ... Vaccines and General Medicine development, has joined the ... as an iMedNet Partner will facilitate Accelovance,s ...
... of Helsinki and Folkhlsan Research Center has identified a ... breeds, the Norwegian Elkhound and the Karelian Bear Dog. ... and a candidate gene for human chondrodysplasias. The finding ... health. A genetic test can now be used to ...
Cached Biology News:Changing laws, attitudes of police response to drug overdose may lead to better outcomes 2MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 2MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 3New dwarfism mutation identified in dogs 2
... medium for the detection, isolation, differentiation ... thyphi) and total coliforms from other ... maximum of 24 hours, needs no ... preparation and performs a higher diagnostic ...
Large-capacity refrigerated incubator chamber holds up to 4 independently-operated shakers. Programmable heat, refrigeration, humidifcation are standard. Photosynthetic operation, optional....
...
... Dynamic Focusing MALDI (PDF-MALDI) source provides fast, ... do not need online separation. Paired with ... and Agilents powerful Spectrum Mill software, the ... of 2D gel-spot digests. It provides clean, ...
Biology Products: